Racial and ethnic disparities in metabolic dysfunctionassociated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of nonalcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

키워드

참고문헌 (19)

1. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
2. Rich NE, "Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States : A systematic review and meta-analysis", Clin Gastroenterol Hepatol, 16, pp.198~210 (2018)
3. Longo M, "TM6SF2", PNPLA3, Cell Mol Gastroenterol Hepatol, pp.2022, 13[DOI]
4. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
5. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
6. Ochoa-Allemant P, "Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States", Hepatol Commun, 7, pp.e0324~ (2023)
7. Nguyen VH, "Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity : A longitudinal realworld study", Clin Mol Hepatol, 29, pp.1002~1012 (2023)
8. Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
9. Kardashian A, "Health disparities in chronic liver disease", Hepatology, 77, pp.1382~1403 (2023)
10. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
11. Eslam M, "MAFLD : A consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
12. Kim KS, "Metabolic dysfunction-associated fatty liver disease and mortality : A population-based cohort study", Diabetes Metab J, 47, pp.220~231 (2023)
13. Younossi ZM, "Lifestyle interventions in nonalcoholic fatty liver disease", Nat Rev Gastroenterol Hepatol, 20, pp.708~722 (2023)
14. Jang H, "Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease", JAMA Intern Med, 184, pp.375~383 (2024)
15. Lazarus JV, "Advancing the global public health agenda for NAFLD : a consensus statement", Nat Rev Gastroenterol Hepatol, 19, pp.60~78 (2022)
16. He J, "Social, behavioral, and metabolic risk factors and racial disparities in cardiovascular disease mortality in U. S. adults : An observational study", Ann Intern Med, 176, pp.1200~1208 (2023)
17. Lazarus JV, "Defining comprehensive models of care for NAFLD", Nat Rev Gastroenterol Hepatol, 18, pp.717~729 (2021)
18. Stender S, "Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci", Nat Genet, 49, pp.842~847 (2017)
19. Eslam M, "Genetic contributions to NAFLD : leveraging shared genetics to uncover systems biology", Nat Rev Gastroenterol Hepatol, 17, pp.40~52 (2020)

관련 논문AI추천